Stocks · News reference

EXCLUSIVE: FDA Approves Quantum BioPharma's Lucid-MS Phase 2 Trial of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination For Progressive Multiple Sclerosis

Aug 10, 2026, 10:30 AMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 10, 2026, 10:30 AM
Checked: Aug 10, 2026, 10:30 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 14, 2026, 6:37 PMBenzinga Newsdesk
Quantum Biopharma shares are trading higher after the company announced it received FDA approval to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis.
Read original at benzinga
QNTM
BenzingaAug 14, 2026, 11:12 AMBenzinga Newsdesk
Quantum BioPharma Says FDA Cleared IND For Lucid-MS Phase 2 Trial In Progressive Multiple Sclerosis; Reports Cash Runway To At Least October 2027
Read original at benzinga
QNTM
BenzingaAug 10, 2026, 10:31 AMVandana Singh
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial
FDA approves Quantum BioPharma's IND application for Lucid-MS, advancing its progressive multiple sclerosis treatment to Phase 2 trials.
Read original at benzinga
QNTM